| Dr Atef F Israel, MD | |
|
4911 S Arrowhead Dr, #300, Independence, MO 64055-7005 | |
| (816) 767-3263 | |
| Not Available |
| Full Name | Dr Atef F Israel |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 47 Years |
| Location | 4911 S Arrowhead Dr, Independence, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700867587 | NPI | - | NPPES |
| 209787308 | Medicaid | MO | |
| 100314320A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | MD109218 (Missouri) | Primary |
| 207LP2900X | Anesthesiology - Pain Medicine | 04-27858 (Kansas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Luke's East Hospital | Lees summit, MO | Hospital |
| Belton Regional Medical Center | Belton, MO | Hospital |
| Centerpoint Medical Center | Independence, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kc Pain Centers Llc | 9335137546 | 9 |
| Kc Pain Centers Llc | 9335137546 | 9 |
News Archive
Analysis of the REVEAL registry shows poor 5-year outcomes for patients with pulmonary arterial hypertension, despite improvements due to targeted therapies.
AtheroMed, Inc. announced today the start of enrollment in the EASE study to evaluate the safety and effectiveness of the Phoenix Atherectomy™ catheter, a minimally invasive device for the treatment of peripheral arterial disease (PAD) in the legs. EASE - Endovascular Atherectomy Safety and Effectiveness - is an FDA-approved Investigational Device Exemption (IDE) clinical trial that will enroll 90 patients at up to 20 clinical sites.
This post in KPLU's "Humanosphere" blog examines the "gap between the disease burden of mental illness and the amount of funding and attention devoted to solving the problem," referencing a post published Friday in the Global Health Interest Forum's "Blog of Scientists for Global Health," written by Paul Southworth, a visiting scholar on malaria and vaccine science at the NIH.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announced today that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone(R) technology for the formulation of fast acting insulin analog formulated with the BioChaperone(R) technology. Consequently, the two companies have terminated the collaboration.
› Verified 8 days ago
| Entity Name | Kc Pain Centers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144211384 PECOS PAC ID: 9335137546 Enrollment ID: O20050228000835 |
News Archive
Analysis of the REVEAL registry shows poor 5-year outcomes for patients with pulmonary arterial hypertension, despite improvements due to targeted therapies.
AtheroMed, Inc. announced today the start of enrollment in the EASE study to evaluate the safety and effectiveness of the Phoenix Atherectomy™ catheter, a minimally invasive device for the treatment of peripheral arterial disease (PAD) in the legs. EASE - Endovascular Atherectomy Safety and Effectiveness - is an FDA-approved Investigational Device Exemption (IDE) clinical trial that will enroll 90 patients at up to 20 clinical sites.
This post in KPLU's "Humanosphere" blog examines the "gap between the disease burden of mental illness and the amount of funding and attention devoted to solving the problem," referencing a post published Friday in the Global Health Interest Forum's "Blog of Scientists for Global Health," written by Paul Southworth, a visiting scholar on malaria and vaccine science at the NIH.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announced today that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone(R) technology for the formulation of fast acting insulin analog formulated with the BioChaperone(R) technology. Consequently, the two companies have terminated the collaboration.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Atef F Israel, MD 10301 Hickman Mills Dr, #100, Kansas City, MO 64137-1674 Ph: (816) 767-3263 | Dr Atef F Israel, MD 4911 S Arrowhead Dr, #300, Independence, MO 64055-7005 Ph: (816) 767-3263 |
News Archive
Analysis of the REVEAL registry shows poor 5-year outcomes for patients with pulmonary arterial hypertension, despite improvements due to targeted therapies.
AtheroMed, Inc. announced today the start of enrollment in the EASE study to evaluate the safety and effectiveness of the Phoenix Atherectomy™ catheter, a minimally invasive device for the treatment of peripheral arterial disease (PAD) in the legs. EASE - Endovascular Atherectomy Safety and Effectiveness - is an FDA-approved Investigational Device Exemption (IDE) clinical trial that will enroll 90 patients at up to 20 clinical sites.
This post in KPLU's "Humanosphere" blog examines the "gap between the disease burden of mental illness and the amount of funding and attention devoted to solving the problem," referencing a post published Friday in the Global Health Interest Forum's "Blog of Scientists for Global Health," written by Paul Southworth, a visiting scholar on malaria and vaccine science at the NIH.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announced today that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone(R) technology for the formulation of fast acting insulin analog formulated with the BioChaperone(R) technology. Consequently, the two companies have terminated the collaboration.
› Verified 8 days ago
Carol A Blum, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1515 W Truman Rd, Suite 108, Independence, MO 64050 Phone: 816-461-3131 Fax: 816-461-1662 | |
Mari A Butterfield, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1515 W Truman Rd, Suite 108, Independence, MO 64050 Phone: 816-461-3131 Fax: 816-461-1662 | |
Ann Elizabeth Pattin, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 19600 E 39th St S, Independence, MO 64057 Phone: 913-428-2900 | |
Stephen C. Ellis, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 19600 E 39th St S, Independence, MO 64057 Phone: 913-428-2900 Fax: 913-428-2951 | |
Dan L Hancock, M. D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 19550 E 39th St Ste 110, Independence, MO 64057 Phone: 816-698-8900 Fax: 816-698-8905 | |
Gregory John Ramirez, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 19600 E 39th St S, Independence, MO 64057 Phone: 913-428-2900 Fax: 913-428-2951 | |
Dr. Edward S Robinson, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 19600 E 39th St S, Independence, MO 64057 Phone: 913-428-2900 Fax: 913-428-2951 |